Effect of conjugated linoleic acid on body fat accretion in overweight or obese children.

BACKGROUND: Conjugated linoleic acid (CLA) is a supplemental dietary fatty acid that decreases fat mass accretion in young animals. OBJECTIVE: The aim of this study was to determine CLA's efficacy with regard to change in fat and body mass index (BMI; in kg/m(2)) in children. DESIGN: We conducted a 7 +/- 0.5-mo randomized, double-blind, placebo-controlled trial of CLA in 62 prepubertal children aged 6-10 y who were overweight or obese but otherwise healthy. The subjects were randomly assigned to receive 3 g/d of 80% CLA (50:50 cis-9,trans-11 and trans-10,cis-12 isomers) or placebo in chocolate milk. RESULTS: Fifty-three subjects completed the trial (n = 28 in the CLA group, n = 25 in the placebo group). CLA attenuated the increase in BMI (0.5 +/- 0.8) compared with placebo (1.1 +/- 1.1) (P = 0.05). The percentage change in body fat measured by dual-energy X-ray absorptiometry was smaller (P = 0.001) in the CLA group (-0.5 +/- 2.1%) than in the placebo group (1.3 +/- 1.8%). The change in abdominal body fat as a percentage of total body weight was smaller (P = 0.02) in the CLA group (-0.09 +/- 0.9%) than in the placebo group (0.43 +/- 0.6%). There were no significant changes in plasma glucose, insulin, or LDL cholesterol between groups. Plasma HDL cholesterol decreased significantly more (P = 0.05) in the CLA group (-5.1 +/- 7.3 mg/dL) than in the placebo group (-0.7 +/- 8 mg/dL). Bone mineral accretion was lower (P = 0.04) in the CLA group (0.05 +/- 0.03 kg) than in the placebo group (0.07 +/- 0.03 kg). Reported gastrointestinal symptoms did not differ significantly between groups. CONCLUSIONS: CLA supplementation for 7 +/- 0.5 mo decreased body fatness in 6-10-y-old children who were overweight or obese but did not improve plasma lipids or glucose and decreased HDL more than in the placebo group. Long-term investigation of the safety and efficacy of CLA supplementation in children is recommended.

A meta-analysis of the effects of conjugated linoleic acid on fat-free mass in humans.

Treatment of laboratory animals with a 50:50 mixture of c9,t11 and t10,c12 conjugated linoleic acid (CLA) results in fat loss and, to a smaller degree, fat-free mass (FFM) gain. In a previous meta-analysis, we found that CLA produced a fat loss, but that humans were not as responsive as mice. We performed a similar meta-analysis in the same 18 studies to test whether CLA increased FFM. Only placebo-controlled trials that measured body composition were included. We found that FFM increased during CLA treatment (0.3 +/- 0.7 kg; p = 0.05), but that the change did not display an effect of length of treatment (0.001 +/- 0.005 kg.week(-1); p = 0.8), or an effect of dosage (0.1 +/- 0.1 kg.g CLA(-1).day(-1); p = 0.3). We conclude that FFM does increase in humans during CLA treatment, but the onset of the increase is rapid and the total increase is small (<1%).

Effects of dietary fatty acid composition on 24-h energy expenditure and chronic disease risk factors in men.

BACKGROUND: A high-fat (HF) diet and sedentary lifestyle are implicated in the development of obesity. Controlled feeding studies and measures of short-term resting energy expenditure (REE) have suggested that the type of dietary fat may alter energy expenditure (EE). OBJECTIVE: The objective was to examine the effects of an HF diet rich in either monounsaturated or saturated fatty acids (FAs) and of exercise on EE and chronic disease risk factors. DESIGN: Eight healthy men [age: 18-45 y; body mass index (in kg/m(2)): 22 +/- 3] were randomly assigned in a 2 x 2 crossover design to 1 of 4 treatments: HF diet (50% of energy) with a high amount of saturated fat (22% of energy) plus exercise (SE) or a sedentary (SS) condition or a diet high in monounsaturated fat (30% of energy) plus exercise (UE) or a sedentary (US) condition. The subjects spent 5 d in a metabolic chamber and cycled at 45% of maximal oxygen uptake for 2 h each day during the exercise visits. Respiratory gases and urinary nitrogen were measured to determine 24-h EE. Resting metabolic rate was measured on days 2, 4, and 6. RESULTS: Average 24-h EE was not different with respect to dietary FA composition (3202 +/- 146, 3208 +/- 151, 2240 +/- 82, and 2270 +/- 104 for SE, UE, SS, and US, respectively). Total and LDL cholesterol and blood pressure were significantly greater after the SE and SS treatments than after the UE and US treatments. CONCLUSION: Resting metabolic rate and 24-h EE were not significantly different after short-term exposure to an HF diet rich in monounsaturated FAs or after exposure to a diet rich in saturated FAs in healthy, nonobese men.

Assessing validity and reliability of resting metabolic rate in six gas analysis systems.

The Deltatrac Metabolic Monitor (DTC) (VIASYS Healthcare Inc, SensorMedics, Yorba Linda, CA), one of the most popular indirect calorimetry systems for measuring resting metabolic rate (RMR) in human subjects, is no longer being manufactured. This study compared five different gas analysis systems to the DTC. RMR was measured by the DTC and at least one other instrument at three study sites for a total of 38 participants. The five indirect calorimetry systems included the MedGraphics CPX Ultima (Medical Graphics Corp, St Paul, MN), the MedGem (Microlife USA, Golden, CO), Vmax Encore 29 System (VIASYS Healthcare Inc, Yorba Linda, CA), the TrueOne 2400 (Parvo Medics, Sandy, UT), and the Korr ReeVue (Korr Medical Technologies, Salt Lake City, UT). Validity was assessed using paired t tests to compare means; reliability was assessed by using both paired t tests and root mean square calculations with F tests for significance. Within-subject comparisons for validity of RMR revealed a significant difference between the DTC and the Ultima system. Bland-Altman plot analysis showed significant bias with increasing RMR values for the Korr and MedGem systems. Respiratory exchange ratio (RER) analysis showed a significant difference between the DTC and the Ultima system and a trend for a difference with the Vmax system (P=0.09). Reliability assessment for RMR revealed that all instruments had a significantly larger coefficient of variation (CV) (ranging from 4.8% to 10.9%) for RMR compared to the 3.0% CV for the DTC. Reliability assessment for RER data showed none of the instrument CVs was significantly larger than the DTC CV. The results were quite disappointing because none of the instruments equaled the within-person reliability of the DTC. The TrueOne and Vmax systems were the most valid instruments in comparison with the DTC for both RMR and RER assessment. Further testing is needed to identify an instrument with the reliability and validity of the DTC.

Conjugated linoleic acid supplementation alters the 6-mo change in fat oxidation during sleep.

BACKGROUND: Conjugated linoleic acid (CLA) is a family of positional and geometric isomers with 2 conjugated double bonds formed from linoleic acid and linolenic acid. CLA has a wide range of biological effects, including body fat reduction. OBJECTIVE: The aim of our study was to determine CLA's effects on energy expenditure, macronutrient utilization, and dietary fat oxidation in overweight adults after 6 mo of supplementation. DESIGN: We recruited 23 subjects from our main CLA efficacy study who were receiving either 4 g/d of 78% active CLA isomers (3.2 g/d: 39.2% cis-9,trans-11 and 38.5% trans-10,cis-12) or 4 g/d of safflower oil. Energy expenditure and substrate utilization were measured before and after 6 mo of CLA supplementation by using whole-room indirect calorimetry. Dietary fat oxidation was measured by using stable isotope-labeled oleate and palmitate. RESULTS: Our substudy detected a difference in the change in fat utilization between the CLA (4 +/- 8 g) and placebo (-7 +/- 11 g) groups during sleep after 6 mo of supplementation. In addition, the percentage of energy from protein was reduced during sleep in the CLA group (CLA: -3.3 +/- 2.6%; placebo: 0.3 +/- 5.7%). We also detected a difference in the change in energy expenditure during sleep (CLA: 0 +/- 38 kcal; placebo: -43 +/- 90 kcal). We did not detect a change in labeled dietary fat oxidation after 6 mo of CLA supplementation given with a breakfast meal. CONCLUSION: Mixed isomer CLA supplementation, but not placebo, positively altered fat oxidation and energy expenditure during sleep.

Efficacy of conjugated linoleic acid for reducing fat mass: a meta-analysis in humans.

BACKGROUND: Conjugated linoleic acid (CLA) has been shown to be an effective supplement for reducing fat mass in animals, whereas results in humans have been inconsistent. OBJECTIVE: This is a meta-analysis of human studies in which CLA was provided as a dietary supplement to test its efficacy in reducing fat mass. DESIGN: We searched the PubMed database (National Library of Medicine, Bethesda, MD) and references from the resulting search to identify studies in which CLA was provided to humans in randomized, double-blinded, placebo-controlled trials and in which body composition was assessed by using a validated technique. RESULTS: We identified 18 eligible studies. Of these, 3 were single-isomer studies, and results comparing CLA isomers were inconclusive. We compared the length of treatment by using studies in which a mixture of purified isomers were used and those in which purified trans-10,cis-12 isomers were used. This comparison indicated that the effect of CLA was linear for up to 6 mo and then slowly approached an asymptote at 2 y. An analysis of the dose effect indicated that fat loss compared with placebo was -0.024 kg x g CLA(-1) x wk(-1) (P=0.03). After adjustment to the median dose of 3.2 g CLA/d, CLA was effective and produced a reduction in fat mass for the CLA group alone (0.05 +/- 0.05 kg/wk; P<0.001) and for the CLA group compared with placebo (0.09 +/- 0.08 kg/wk; P<0.001) CONCLUSION: Given at a dose of 3.2 g/d, CLA produces a modest loss in body fat in humans.

Bioelectrical impedance vs. four-compartment model to assess body fat change in overweight adults.

OBJECTIVE: The Tanita TBF-305 body fat analyzer is marketed for home and clinical use and is based on the principles of leg-to-leg bioelectrical impedance analysis (BIA). Few studies have investigated the ability of leg-to-leg BIA to detect change in percentage fat mass (%FM) over time. Our objective was to determine the ability of leg-to-leg BIA vs. the four-compartment (4C) model to detect small changes in %FM in overweight adults. RESEARCH METHODS AND PROCEDURES: Thirty-eight overweight adults (BMI, 25.0 to 29.9 kg/m2; age, 18 to 44 years; 31 women) participated in a 6-month, randomized, double-blind, placebo-controlled study of a nutritional supplement. Body composition was measured at 0 and 6 months using the Tanita TBF-305 body fat analyzer [using equations derived by the manufacturer (%FM(T-Man)) and by Jebb et al. (%FM(T-Jebb))] and the 4C model (%FM(4C)). RESULTS: Subjects in the experimental group lost 0.9%FM(4C) (p = 0.03), a loss that did not reach significance using leg-to-leg BIA (0.6%FM(T-Man), p = 0.151; 0.6%FM(T-Jebb), p = 0.144). We observed large standard deviations (SDs) in the mean difference in %FM between the 4C model and the Tanita(Manufacturer) (2.5%) and Tanita(Jebb) (2.2%). Ten subjects fell outside +/-1 SD of the mean differences at 0 and 6 months; those individuals were younger and shorter than those within +/-1 SD. DISCUSSION: Leg-to-leg BIA performed reasonably well in predicting decreases in %FM in this group of overweight adults but resulted in wide SDs vs. %FM(4C) in individuals. Cross-sectional determinations of %FM of overweight individuals using leg-to-leg BIA should be interpreted with caution.